ArticleJournal of orthopaedic translation2026
The PTBP1-EZH2-DOCK2 axis promotes M1 microglial polarization and exacerbates neuronal apoptosis following spinal cord injury.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing the continuum of orthopaedic translation: Mechanistic insight, regenerative innovation, and converging technologies.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Microglial M1 polarization plays a critical role in secondary injury following spinal cord injury (SCI) by promoting the release of inflammatory factors and inducing neuronal apoptosis. This study aims to investigate the regulatory mechanism of the polypyrimidine tract-binding protein 1 (PTBP1)-enhancer of zeste homolog 2 (EZH2)-dedicator of cytokinesis 2 (DOCK2) axis in microglial polarization and to analyze its impact on neuronal apoptosis, thereby uncovering potential mechanisms underlying SCI pathophysiology. Methods: A SCI rat model was established, with expression regulated via lentiviral infection. Motor function was evaluated using behavioral assessments, while hematoxylin and eosin (HE) staining, immunofluorescence (IF), co-staining of TUNEL/NeuN, Nissl staining, and Western blotting (WB) were performed to evaluate spinal cord pathology, microglial polarization, inflammation, and neuronal apoptosis, respectively. In HMC3 cells, flow cytometry, IF, WB, actinomycin D treatment, RIP-qPCR, ChIP-qPCR, and dual-luciferase reporter assays were utilized to investigate the regulatory interactions among PTBP1, EZH2, and DOCK2 and their impacts on microglial polarization. Co-culture of HMC3 with SH-SY5Y cells were conducted to evaluate the effect of microglial polarization on neuronal apoptosis. Results: In both SCI rats and lipopolysaccharide (LPS)-treated HMC3 cells, expression of PTBP1, EZH2, and DOCK2 was significantly upregulated. Mechanistic analysis revealed that PTBP1 enhanced EZH2 mRNA stability, increasing EZH2 expression. Moreover, EZH2 promoted DOCK2 transcription in manner independent of the polycomb repressive complex 2 (PRC2), histone methylation, and DNA methylation. Inhibition of the PTBP1-EZH2-DOCK2 axis promoted the shift of HMC3 cells toward M2 polarization. Restoration of the M1/M2 microglial balance attenuated neuronal apoptosis and inflammatory responses. Conclusion: PTBP1 enhances EZH2 mRNA stability to upregulate DOCK2 transcription, driving microglial polarization toward the M1 phenotype. This mechanism aggravates neuronal apoptosis and inflammation, ultimately contributing to the progression of SCI pathology. The Translational Potential of this Article: This study reveals the PTBP1-EZH2-DOCK2 axis as a potential molecular basis for intervening in aberrant microglial polarization and developing novel therapeutic targets for SCI. This research possesses significant potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.